logo
Twitter
Discord
Email
logo
Chemed Corporation

Chemed Corporation

NYSE•CHE
CEO: Mr. Kevin J. McNamara
Sector: Healthcare
Industry: Medical - Care Facilities
Listing Date: 1973-05-03
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Contact Information
255 East Fifth Street, Suite 2600, Cincinnati, OH, 45202-4726, United States
513-762-6690
www.chemed.com
Market Cap
$6.58B
P/E (TTM)
23.6
16.2
Dividend Yield
0.5%
52W High
$623.61
52W Low
$408.42
52W Range
20%
Rank16Top 3.7%
6.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$624.90M+3.09%
4-Quarter Trend

EPS

$4.46-11.51%
4-Quarter Trend

FCF

$66.03M-14.22%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Consolidated Revenue Growth Service revenues reached $1.89B for nine months, reflecting 5.5% growth, primarily driven by VITAS segment performance.
VITAS Segment Leads Growth VITAS revenue increased 8.2% to $1.21B, supported by 6.6% rise in days-of-care and 3.8% reimbursement rate increase.
Strong Liquidity Maintained Company maintains satisfactory liquidity with $404.5M of unused lines of credit available under the revolving credit facility.
Share Repurchase Authorization Board authorized additional $300.0M for repurchases; $301.8M authorization remains available under the current plan.

Risk Factors

VITAS Medicare Cap Pressure VITAS gross margin declined due to $18.8M increase in Medicare Cap liability and higher variable patient care expenses.
Roto-Rooter Margin Compression Roto-Rooter gross margin fell to 50.2% due to increased variable expenses, including a $5.8M casualty insurance increase.
Cybersecurity Incident Impact VITAS experienced a data breach involving PHI; investigation ongoing regarding full scope and potential regulatory notification requirements.
Consolidated Net Income Nine-month net income declined to $188.5M from $211.7M, impacted by lower operating income and increased liabilities.

Outlook

Future Cost Management Evaluating pricing actions and cost savings efforts for fiscal year 2026 planning amid ongoing economic pressures and inflation.
Debt Covenant Compliance Management anticipates remaining in compliance with all quarterly financial covenants throughout the foreseeable future period.
Capital Deployment Strategy Continually evaluating capital utilization alternatives including share repurchase, debt repurchase, and potential acquisition opportunities.
New Tax Disclosure Finalized Finalizing impact analysis for ASU 2023-09 Income Tax Disclosure, expecting incorporation into future Annual Report footnotes.

Peer Comparison

Revenue (TTM)

Universal Health Services, Inc.UHS
$16.99B
+10.2%
Encompass Health CorporationEHC
$5.80B
+11.1%
Select Medical Holdings CorporationSEM
$5.37B
-23.0%

Gross Margin (Latest Quarter)

Acadia Healthcare Company, Inc.ACHC
96.4%
+0.1pp
Universal Health Services, Inc.UHS
90.8%
+0.6pp
Enhabit, Inc.EHAB
48.5%
+0.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
UHS$12.89B9.419.9%33.3%
ENSG$10.46B31.616.6%41.3%
EHC$10.11B18.724.4%38.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.8%
Flat Growth
4Q Net Income CAGR
-10.7%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 25, 2026
|
EPS:$7.02
|
Revenue:$658.97M
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 31, 2025|
    Revenue: $624.90M+3.1%
    |
    EPS: $4.46-11.5%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 31, 2025|
    Revenue: $618.80M+3.8%
    |
    EPS: $3.60-23.4%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: Apr 28, 2025|
    Revenue: $646.94M+9.8%
    |
    EPS: $4.91+14.2%
    Miss

  • Form 10-K/A - FY 2024

    Period End: Dec 31, 2024|Filed: Apr 1, 2025|
    Revenue: $2.43B+7.4%
    |
    EPS: $20.10+11.0%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 28, 2025|Refer to amended data

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 1, 2024|
    Revenue: $606.18M+7.4%
    |
    EPS: $5.04+1.4%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Jul 26, 2024|
    Revenue: $595.88M+7.6%
    |
    EPS: $4.70+32.8%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: Apr 29, 2024|
    Revenue: $589.23M+5.2%
    |
    EPS: $4.30+18.8%
    Miss